Allogeneic versus syngeneic killer splenocytes as effector cells for the induction of graft-versus-tumor effect

Biology of Blood and Marrow Transplantation

Volumn 10, Issue 1, 2004, Pages 40-48

  Morecki, Shoshana ^a   Yacovlev, Elena ^a   Gelfand, Yael ^a   Vilensky, Anna ^a   Slavin, Shimon ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Allogeneic killer cells; Graft versus tumor effect; SCID mice; Syngeneic killer cells

Indexed keywords

CD3 ANTIGEN; CD8 ANTIGEN; RECOMBINANT INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; DISEASE SEVERITY; EFFECTOR CELL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IN VITRO STUDY; INOCULATION; INTERMETHOD COMPARISON; ISOGRAFT; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MINOR HISTOCOMPATIBILITY COMPLEX; MORTALITY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PROBABILITY; SCID MOUSE; SPLEEN CELL; SURVIVAL; TUMOR CELL; TUMOR GROWTH; WHOLE BODY RADIATION;

ANIMALS; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HISTOCOMPATIBILITY; KILLER CELLS, LYMPHOKINE-ACTIVATED; LYMPHOCYTE TRANSFUSION; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, SCID; SPLEEN; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; TRANSPLANTATION, ISOGENEIC;

EID: 0742323846     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbmt.2003.09.013     Document Type: Article

References (41)

1. Rosenberg S.A. Lotze M.T. Yang J.C. et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer J Natl Cancer Inst. 85 1993 622-632
2. Fefer A. Benyunes M. Higuchi C. et al. Interleukin-2 +/- lymphocytes as consolidative immunotherapy after autologous bone marrow transplantation for hematologic malignancies Acta Haematol. 89 suppl 1 1993 2-7
3. Slavin S. Naparstek E. Or R. Weiss L. Prevention of GVHD and induction of graft vs leukemia (GVL) effects: will it ever be possible? Bone Marrow Transplant. 3 1988 208-209
4. Slavin S. Ackerstein A. Nagler A. Naparstek E. Weiss L. Cell-mediated cytokine-activated immunotherapy (CCI) of malignant hematological disorders for eradication of minimal residual disease (MRD) in conjunction with conventional chemotherapy or bone marrow transplantation (BMT) Blood 76 suppl 1 1990 566a (abstr.)
5. Slavin S. Naparstek E. Nagler A. Ackerstein A. Kapelushnik Y. Or R. Allogeneic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes Exp Hematol. 23 1995 1553-1562
6. Slavin S. Immunotherapy of cancer with alloreactive lymphocytes Lancet Oncol. 2 2001 491-498
7. Verneris M.R. Baker J. Edinger M. Negrin R.S. Studies of ex vivo activated and expanded CD8+ NK-T cells in humans and mice J Clin Immunol. 22 2002 131-136
8. Rosenberg S.A. Packard B.S. Aebersold P.M. et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report N Engl J Med. 319 1988 1676-1680
9. Falkenburg J.H. Wafelman A.R. Joosten P. et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes Blood 94 1999 1201-1208
10. Slavin S. Ackerstein A. Morecki S. Gelfand Y. Cividalli G. Immunotherapy of relapsed resistant chronic myelogenous leukemia post allogeneic bone marrow transplantation with alloantigen pulsed donor lymphocytes Bone Marrow Transplant. 28 2001 795-798
11. Dudley M.E. Wunderlich J.R. Robbins P.F. et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes Science 298 2002 850-854
12. Weiden P.L. Sullivan K.M. Flournoy N. Storb R. Thomas E.D. Antileukemic effect of chronic graft- versus-host disease: contribution to improved survival after allogeneic marrow transplantation N Engl J Med. 304 1981 1529-1533
13. Kolb H.J. Mittermuller J. Clemm C. et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients Blood 76 1990 2462-2465
14. Collins R.H. Jr. Shpilberg O. Drobyski W.R. et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation J Clin Oncol. 15 1997 433-444
15. Slavin S. Morecki S. Weiss L. et al. Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation J Hematother Stem Cell Res. 11 2002 265-276
16. Weiss L. Reich S. Slavin S. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 2. The role of non-activated and rIL-2-activated CD4+ and CD8+ T cells in immunotherapy for leukemia Cytokines Cell Mol Ther. 5 1999 153-158
17. Murphy W.J. Longo D.L. The potential role of NK cells in the separation of graft-versus-tumor effects from graft-versus-host disease after allogeneic bone marrow transplantation Immunol Rev. 157 1997 167-176
18. Asai O. Longo D.L. Tian Z.G. et al. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation J Clin Invest. 101 1998 1835-1842
19. Ruggeri L. Capanni M. Martelli M.F. Velardi A. Cellular therapy: exploiting NK cell alloreactivity in transplantation Curr Opin Hematol. 8 2001 355-359
20. Ruggeri L. Capanni M. Urbani E. et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants Science 295 2002 2097-2100
21. Karre K. Ljunggren H.G. Piontek G. Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy Nature 319 1986 675-678
22. Seaman W.E. Natural killer cells and natural killer T cells Arthritis Rheum. 43 2000 1204-1217
23. Smyth M.J. Hayakawa Y. Takeda K. Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer Nat Rev Cancer. 2 2002 850-861
24. Ferrara J.L. Deeg H.J. Graft-versus-host disease N Engl J Med. 324 1991 667-674
25. Crawford S.W. Longton G. Storb R. Acute graft-versus-host disease and the risks for idiopathic pneumonia after marrow transplantation for severe aplastic anemia Bone Marrow Transplant. 12 1993 225-231
26. Kolb H.J. Schattenberg A. Goldman J.M. et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia Blood 86 1995 2041-2050
27. Ueno N.T. Rondon G. Mirza N.Q. et al. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer J Clin Oncol. 16 1998 986-993
28. Dexter D.L. Kowalski H.M. Blazar B.A. Fligiel Z. Vogel R. Heppner G. Heterogeneity of tumor cells from a single mouse mammary tumor Cancer Res. 38 1978 3174-3181
29. Morecki S. Yacovlev E. Diab A. Slavin S. Allogeneic cell therapy for a murine mammary carcinoma Cancer Res. 58 1988 3891-3895
30. Kiessling R. Klein E. Wigzell H. "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype Eur J Immunol. 5 1975 112-117
31. Morecki S. Gelfand Y. Nagler A. et al. Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen Bone Marrow Transplant. 28 2001 243-249
32. Pulaski B.A. Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines Cancer Res. 58 1998 1486-1493
33. Morecki S. Leshem B. Weigensberg M. Bar S. Slavin S. Functional clonal deletion versus active suppression in transplantation tolerance induced by total-lymphoid irradiation Transplantation 40 1985 201-210
34. Kaplan E. Non-parametric estimation from incomplete observation J Am Stat Assoc. 53 1958 457-481
35. Breslow W. A generalized Kruskal-Wallis test for comparing K sample subject to unequal patterns of censorship Biomedika. 57 1970 579-594
36. Morecki S. Yacovlev E. Gelfand Y. Uzi I. Slavin S. Cell therapy with preimmunized effector cells mismatched for minor histocompatible antigens in the treatment of a murine mammary carcinoma J Immunother. 24 2001 114-121
37. Yu Y.Y. George T. Dorfman J.R. Roland J. Kumar V. Bennett M. The role of Ly49A and 5E6(Ly49C) molecules in hybrid resistance mediated by murine natural killer cells against normal T cell blasts Immunity 4 1996 67-76
38. Ashkenazi A. Dixit V.M. Death receptors: signaling and modulation Science 281 1998 1305-1308
39. Smyth M.J. Cretney E. Takeda K. et al.Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis J Exp Med. 193 2001 661-670
40. Diefenbach A. Raulet D.H. Innate immune recognition by stimulatory immunoreceptors Curr Opin Immunol. 15 2003 37-44
41. Koh C.Y. Blazar B.R. George T. et al. Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo Blood 97 2001 3132-3137